PV 113

Drug Profile

PV 113

Latest Information Update: 25 Aug 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Anxiolytics; Nootropics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Learning disorders

Most Recent Events

  • 25 Aug 1998 No-Development-Reported for Anxiety disorders in Russia (Unknown route)
  • 25 Aug 1998 No-Development-Reported for Learning disorders in Russia (Unknown route)
  • 20 Feb 1996 PV 113 is being investigated for use in Alzheimer's Disease and Cognition Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top